Semliki Forest virus-mediated gene therapy of the RG2 rat glioma

Neuropathology and Applied Neurobiology
F P RocheG J Atkins

Abstract

Glioblastoma multiforme is the most common and most malignant adult brain tumour. Despite numerous advances in cancer therapy there has been little change in the prognosis of glioblastoma multiforme, which remains invariably fatal. We examined the Semliki Forest virus virus-like particle (SFV VLP) expression system encoding interleukin-12 (IL-12) as a therapeutic intervention against the syngeneic RG2 rat glioma model. Glioma-bearing rats were treated with IL-12-encoding SFV VLPs via an implanted cannula. Animals were treated with 5 × 10⁷ (low-dose) or 5 × 10⁸ (high-dose) VLPs per treatment and the effect on glioma growth and survival was assessed. Low-dose treatment produced a 70% reduction in tumour volume, associated with a significant extension (20.45%) in survival that was dependent upon IL-12 expression. High-dose treatment resulted in an 87% reduction in tumour volume, related to the oncolytic capacity of the SFV VLP system. VLP delivery to the central nervous system (CNS) demonstrated the potential of the vector system to induce lethal pathology that was unrelated to replication-competent virus or high-level IL-12 expression. Treatment-related death was pronounced in high dose-treated animals and appeared to be the resu...Continue Reading

References

Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·S H ChenS L Woo
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·M CarusoS H Chen
May 1, 1997·Journal of Neuro-oncology·P WesselingP C Burger
Feb 28, 1998·Immunologic Research·G Trinchieri
Oct 21, 1998·The Journal of General Virology·G M GlasgowG J Atkins
Jan 9, 1999·Journal of Virology·C Smerdou, P Liljeström
Jan 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·F J MurphyP R Burd
Feb 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·J N ParkerJ M Markert
Aug 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M J SmythS E Street
Feb 24, 2001·Journal of Immunotherapy·B ChenI Fodor
Feb 5, 2003·Journal of Biomedical Science·Ian F Parney, Lung-Ji Chang
Mar 22, 2003·Cancer Immunology, Immunotherapy : CII·Johanna E A PortieljeWim H J Kruit
Jan 7, 2004·Nature Reviews. Cancer·Glenn Dranoff
Jun 21, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Juan R Rodriguez-MadozCristian Smerdou
Jan 21, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Audrey GrahamJohn K Fazakerley
Feb 20, 2007·Molecular Aspects of Medicine·Sonia MinuzzoAlberto Amadori
Feb 27, 2007·Cytokine & Growth Factor Reviews·Osvaldo L PodhajcerGuillermo Mazzolini
Apr 20, 2007·International Journal of Cancer. Journal International Du Cancer·Ann-Marie MäättäJarmo Wahlfors
Aug 2, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Juan R Rodriguez-MadozCristian Smerdou

❮ Previous
Next ❯

Citations

Jan 21, 2016·Immunotherapy·Ruben Hernandez-AlcocebaCristian Smerdou
Aug 22, 2012·Neuroscience Letters·NaTosha N GatsonBalveen Kaur
Aug 27, 2015·Virus Research·Kenneth Lundstrom
Nov 10, 2016·Vaccines·Kenneth Lundstrom
Apr 19, 2017·Vaccines·Kenneth Lundstrom
Sep 6, 2014·Cell Death and Differentiation·S TuguesB Becher
Nov 10, 2011·Toxins·Massimo S FiandacaKrystof S Bankiewicz
Jun 9, 2018·Diseases·Kenneth Lundstrom
Nov 13, 2020·Frontiers in Immunology·Khue G NguyenDavid A Zaharoff
Apr 2, 2021·Frontiers in Molecular Neuroscience·Kaushik BanerjeeMaria G Castro

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.